- Home
- MDAI vs APRE Comparison
MDAI vs APRE Comparison
Compare MDAI & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDAI
- APRE
- Stock Information
- Founded
- MDAI 2013
- APRE 2006
- Country
- MDAI United States
- APRE United States
- Employees
- MDAI N/A
- APRE N/A
- Industry
- MDAI Medical/Dental Instruments
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MDAI Health Care
- APRE Health Care
- Exchange
- MDAI Nasdaq
- APRE Nasdaq
- Market Cap
- MDAI 21.3M
- APRE 20.2M
- IPO Year
- MDAI N/A
- APRE 2019
- Fundamental
- Price
- MDAI $1.43
- APRE $4.18
- Analyst Decision
- MDAI Strong Buy
- APRE Strong Buy
- Analyst Count
- MDAI 3
- APRE 2
- Target Price
- MDAI $4.50
- APRE $15.50
- AVG Volume (30 Days)
- MDAI 211.4K
- APRE 47.0K
- Earning Date
- MDAI 11-11-2024
- APRE 11-07-2024
- Dividend Yield
- MDAI N/A
- APRE N/A
- EPS Growth
- MDAI N/A
- APRE N/A
- EPS
- MDAI N/A
- APRE N/A
- Revenue
- MDAI $22,531,000.00
- APRE $1,275,686.00
- Revenue This Year
- MDAI $60.11
- APRE $96.15
- Revenue Next Year
- MDAI N/A
- APRE N/A
- P/E Ratio
- MDAI N/A
- APRE N/A
- Revenue Growth
- MDAI 0.30
- APRE 410.91
- 52 Week Low
- MDAI $0.82
- APRE $2.15
- 52 Week High
- MDAI $3.72
- APRE $8.85
- Technical
- Relative Strength Index (RSI)
- MDAI 63.04
- APRE 70.47
- Support Level
- MDAI $1.20
- APRE $2.15
- Resistance Level
- MDAI $1.30
- APRE $5.01
- Average True Range (ATR)
- MDAI 0.12
- APRE 0.43
- MACD
- MDAI 0.04
- APRE 0.22
- Stochastic Oscillator
- MDAI 93.99
- APRE 70.98
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).